Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has introduced Amethia Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg) tablets, the generic version of Teva Women's Health's LoSEASONIQUE, indicated to prevent pregnancy.
Subscribe to our email newsletter
The launch follows a settlement with Teva Women’s Health.
The global marketing research company for the pharmaceutical industry, IMS Health said Watson is the first applicant to submit a complete ANDA and is eligible for 180 days of shared generic market exclusivity.
The data further revealed that LoSEASONIQUE had registered sales of around $28m for the most recent twelve months ending 30 September 2011.
The terms of the deal have not been revealed.